3//SEC Filing
WALTERS GROUP 3
Accession 0001213900-26-002566
CIK 0001725160other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:56 PM ET
Size
8.7 KB
Accession
0001213900-26-002566
Insider Transaction Report
Form 3
WALTERS GROUP
10% Owner
Holdings
- 7,050,000
Common Stock
WALTERS WILLIAM THURMAN
10% Owner
Holdings
- 7,050,000
Common Stock
WALTERS SUSAN BERKLEY
10% Owner
Holdings
- 7,050,000
Common Stock
Footnotes (2)
- [F1]The shares of common stock reported herein (the "Shares") are held directly by The Walters Group (the "TWG"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose.
- [F2]On December 15, 2025, Zentalis Pharmaceuticals, Inc. (the "Issuer") entered into a Stock Purchase Agreement (the "Agreement") with Matrix Capital Master Fund, LP ("Matrix"). Pursuant to the Agreement, the Issuer agreed to repurchase 7,500,000 shares of the Issuer's common stock from Matrix (the "Repurchase"). The Repurchase closed on December 15, 2025 and is further described in the Form 8-K filed by the Issuer with the U.S. Securities and Exchange Commission on December 15, 2025. As a result of the Repurchase, the Reporting Persons are deemed to be 10% holders. This status is not the result of any acquisition of securities by the Reporting Persons.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001177523
Filing Metadata
- Form type
- 3
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 4:56 PM ET
- Size
- 8.7 KB